ObjectiveTo explore the possible mechanisms by which ligustilide （LIG） exerts neuroprotective effects on ischemic stroke （IS） by inhibiting the release of neutrophil extracellular traps （NETs）， promoting blood-brain barrier repair， and alleviating post-ischemic neuroinflammation， thereby providing a new direction for IS treatment. MethodsA middle cerebral artery occlusion （MCAO） model was established in rats. The rats were divided into the sham operation （Sham） group， model （Model） group， low- and high-dose LIG groups （20， 40 mg·kg^-1）， and the NET inhibitor CI-amidine group （CI-amidine， 10 mg·kg^-1）. Drug treatments were administered for 3 days. Neurological injury after ischemia was evaluated by 2，3，5-triphenyltetrazolium chloride （TTC） staining， neurological deficit scoring， and brain index measurement. Flow cytometry and Western blot were used to analyze changes in neutrophil expression. Immunofluorescence was used to observe the fluorescence intensity of the NET marker citrullinated histone H3 （H3Cit）. Western blot was performed to detect the expression of blood-brain barrier tight junction-related proteins and inflammatory factors， including interleukin-18 （IL-18） and interleukin-1β （IL-1β）. ResultsCompared with the Sham group， the Model group exhibited significant brain tissue injury （P<0.05）， significantly increased neutrophil numbers and NET expression （P<0.05）， significantly impaired blood-brain barrier permeability （P<0.05）， and significantly increased expression of inflammatory factors （P<0.05）. Compared with the Model group， both low- and high-dose LIG significantly alleviated brain tissue injury in rats （P<0.01）， inhibited neutrophil numbers and NET expression （P<0.01）， reduced blood-brain barrier damage （P<0.01）， and suppressed the expression of inflammatory factors IL-18 and IL-1β （P<0.01）， thereby ultimately exerting a neuroprotective effect. ConclusionThe neuroprotective effect of LIG in rats with cerebral ischemia-reperfusion injury may be related to inhibition of neutrophils and the NETs induced by them.

ObjectiveTo explore the possible mechanisms by which ligustilide （LIG） exerts neuroprotective effects on ischemic stroke （IS） by inhibiting the release of neutrophil extracellular traps （NETs）， promoting blood-brain barrier repair， and alleviating post-ischemic neuroinflammation， thereby providing a new direction for IS treatment. MethodsA middle cerebral artery occlusion （MCAO） model was established in rats. The rats were divided into the sham operation （Sham） group， model （Model） group， low- and high-dose LIG groups （20， 40 mg·kg^-1）， and the NET inhibitor CI-amidine group （CI-amidine， 10 mg·kg^-1）. Drug treatments were administered for 3 days. Neurological injury after ischemia was evaluated by 2，3，5-triphenyltetrazolium chloride （TTC） staining， neurological deficit scoring， and brain index measurement. Flow cytometry and Western blot were used to analyze changes in neutrophil expression. Immunofluorescence was used to observe the fluorescence intensity of the NET marker citrullinated histone H3 （H3Cit）. Western blot was performed to detect the expression of blood-brain barrier tight junction-related proteins and inflammatory factors， including interleukin-18 （IL-18） and interleukin-1β （IL-1β）. ResultsCompared with the Sham group， the Model group exhibited significant brain tissue injury （P<0.05）， significantly increased neutrophil numbers and NET expression （P<0.05）， significantly impaired blood-brain barrier permeability （P<0.05）， and significantly increased expression of inflammatory factors （P<0.05）. Compared with the Model group， both low- and high-dose LIG significantly alleviated brain tissue injury in rats （P<0.01）， inhibited neutrophil numbers and NET expression （P<0.01）， reduced blood-brain barrier damage （P<0.01）， and suppressed the expression of inflammatory factors IL-18 and IL-1β （P<0.01）， thereby ultimately exerting a neuroprotective effect. ConclusionThe neuroprotective effect of LIG in rats with cerebral ischemia-reperfusion injury may be related to inhibition of neutrophils and the NETs induced by them.

This article presents the first reported successful case of patent ductus arteriosus closure using a fully biodegradable occluder under the sole guidance of transthoracic echocardiography.Compared to traditional methods that require radiation and metal occluders,this technique,which combines echocardiography guidance with biodegradable devices,reduces iatrogenic injury and procedural risks,demonstrating favorable clinical outcomes.

Objective To investigate the efficacy and safety of unilateral biportal endoscopic transforaminal lumbar interbody fusion(UBE-TLIF),minimally invasive transforaminal lumbar interbody fusion(MIS-TLIF),and posterior lumbar interbody fusion(PLIF)in patients with lumbar disc degenerative change.Methods The medical records of 101 patients with lumbar disc degenerative change who underwent surgical treatment in our hospital from January 2019 to December 2022 were retrospectively collected,and they were divided into UBE-TLIF group(37 cases),MIS-TLIF group(33 cases)and PLIF group(31 cases)according to types of operation.The operation related indexes,visual analogue scale(VAS),dysfunction and postoperative complications of the three groups were compared.The height of the intervertebral space and the lumbar lordosis angle were measured before and after surgery.Interbody fusion 12 months after surgery were evaluated via Bridwell criteria.Results The duration of operation of UBE-TLIF group was significantly longer than that of MIS-TLIF group and PLIF group,and MIS-TLIF group was significantly longer than that of PLIF group,the differences were statistically significant(P＜0.05);The intraoperative blood loss and postoperative drainage volume in the UBE-TLIF group were significantly less than those in the MIS-TLIF group and PLIF group,and the MIS-TLIF group was significantly less than that in the PLIF group,the postoperative hospital stay in the UBE-TLIF group was significantly shorter than that in the MIS-TLIF group and PLIF group,and the MIS-TLIF group was significantly shorter than that in the PLIF group,the differences were statistically significant(P＜0.05);The VAS of low back pain and leg pain at 1,3,and 12 months after operation in the 3 groups were significantly lower than those before operation(P＜0.05);The VAS of low back pain and leg pain at 1 and 3 months after operation in the UBE-TLIF group was significantly lower than that in the MIS-TLIF group and the PLIF group,and the VAS of low back pain and leg pain in the MIS-TLIF group was significantly lower than that in the PLIF group(P＜0.05);The Oswestry disability index(ODI)at 1,3 and 12 months after operation in the 3 groups was significantly lower than that before operation,and the ODI in UBE-TLIF group was significantly lower than that in MIS-TLIF group and PLIF group at 1 month after operation,the differences were statistically significant(P＜0.05);The intervertebral space height and lumbar lordosis angle at 1,3,and 12 months after operation were significantly bigger than those before operation in 3 groups(P＜0.05);At 12 months after operation,the intervertebral fusion rates of UBE-TLIF group,MIS-TLIF group and PLIF group were 94.59%,93.94%and 93.55%,respectively,showing no significant difference among the 3 groups(P＞0.05);The interbody fusion time in UBE-TLIF group and MIS-TLIF group was significantly shorter than that in PLIF group(P＜0.05);There was no significant difference in the incidence of complications among the three groups(P＞0.05).Conclusion UBE-TLIF,MIS-TLIF and PLIF can all achieve a higher interbody fusion rate in treating lumbar disc degenerative change,and UBE-TLIF and MIS-TLIF cause less serious surgical trauma,while UBE-TLIF outperforms MIS-TLIF in respect of surgical trauma,and sees faster postoperative recovery.

Oral and maxillofacial CBCT(cone beam computed tomography)as a kind of oral imaging techniques,can accurately show the tooth pulp in an all-round way.Especially for showingthe morphologyof special root canals,it has incomparable advantages over two-dimensional X ray film.With the development of digital technology and artificial intelligence technology,CBCT has been widely used in stomatology.In this paper,we will systematically review the applicationprogress of CBCT combined with oral digital technology and arti-ficial intelligence technology,with a view to providing references for clinical diagnosis and treatmentand technical development of the discipline.

By establishing a complete data organizational structure,technical architecture,quality control framework,and concept framework,hospitals can effectively regulate data management,data security,and quality monitoring,achieving full-cycle monitoring of data management.Breaking down the resource barriers of data systems,improving the efficiency of data usage and circulation,and promoting the increase in data value.It drives the hospital's scientific research innovation,medical insurance cost control,data value monetization,and the improvement of high-quality capabilities.Through the establishment of a sustainable digital culture and operational philosophy,it integrates data with hospital assets,continuously enhancing the value realization of hospital data in operations,management,diagnosis and treatment,and scientific research.

The development of surgery brings about the transformation of surgeons′ con-cepts, and in turn, each renewal of surgical concepts propels progress of surgical techniques. These two aspects complement each other. The treatment of hepatocellular carcinoma is a comprehensive therapy centered on surgery. With the deepening understanding of liver anatomy, the surgical methods have evolved from initial local resection to anatomical liver resection, and then to resection of the tumor-bearing portal vein territory. In recent years, with the emergence of hepatic membrane anatomy, portal plate theory, and three-dimensional visualization, the theoretical and technical systems of laparoscopic anatomical liver resection has become more and more mature. Based on own experience and literature reports, the authors systematically elaborate on the construction of theoretical and technological systems of laparoscopic anatomic liver resection for hepatocellular carcinoma, for reference by colleagues.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, with few effective treatments currently available. The multifactorial nature of AD, shaped by genetic, environmental, and biological factors, complicates both research and clinical management. Recent advances in artificial intelligence (AI) and multi-omics technologies provide new opportunities to elucidate the molecular mechanisms of AD and identify early biomarkers for diagnosis and prognosis. AI-driven approaches such as machine learning, deep learning, and network-based models have enabled the integration of large-scale genomic, transcriptomic, proteomic, metabolomic, and microbiomic datasets. These efforts have facilitated the discovery of novel molecular signatures and therapeutic targets. Methods including deep belief networks and joint deep semi-non-negative matrix factorization have contributed to improvements in disease classification and patient stratification. However, ongoing challenges remain. These include data heterogeneity, limited interpretability of complex models, a lack of large and diverse datasets, and insufficient clinical validation. The absence of standardized multi-omics data processing methods further restricts progress. This review systematically summarizes recent advances in AI-driven multi-omics research in AD, highlighting achievements in early diagnosis and biomarker discovery while discussing limitations and future directions needed to advance these approaches toward clinical application.

By establishing a complete data organizational structure,technical architecture,quality control framework,and concept framework,hospitals can effectively regulate data management,data security,and quality monitoring,achieving full-cycle monitoring of data management.Breaking down the resource barriers of data systems,improving the efficiency of data usage and circulation,and promoting the increase in data value.It drives the hospital's scientific research innovation,medical insurance cost control,data value monetization,and the improvement of high-quality capabilities.Through the establishment of a sustainable digital culture and operational philosophy,it integrates data with hospital assets,continuously enhancing the value realization of hospital data in operations,management,diagnosis and treatment,and scientific research.

Osteoarthritis(OA),a common age-related chronic disease,is characterized by degenerative changes in the joints and surrounding tissues.Traditionally,research on OA has primarily focused on the pathological changes in articular cartilage and its repair.However,with the advancements in animal disease modeling in recent years,especially the widespread use of spatiotemporally specific transgenic mouse models,scholars have gradually come to realize that the subchondral bone also plays an important role in the occurrence and development of OA.That is,the pathological changes in articular cartilage and bone mutually affect and promote each other,jointly driving the progression of OA,involving such pathological processes as vascular invasion,ectopic calcification,nerve growth,and the occurrence of pain.Given the complexity of cartilage-bone pathological relationship,it is difficult to conduct in-depth research on subchondral bone pathology using clinical human samples,or to simulate the pathological processes of OA through in vitro cell experiments.Therefore,animal models play an irreplaceable role in investigating the pathological mechanisms of OA and developing clinical drugs.This review,in addition to providing an overview of OA animal models,synthesizes the latest progress in animal experimental research on OA,highlighting the active role of the cartilage-bone pathological relationship in OA progression.These new findings provide references for future in-depth investigations and also provide a theoretical basis for developing fundamental strategies for OA prevention and treatment.